^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Circulating miR-146a expression predicts early treatment response to imatinib in adult chronic myeloid leukemia

Published date:
11/10/2020
Excerpt:
Sixty patients with CML and 20 healthy controls were recruited in this study...Using ROC curve analysis, it was found that miR-146a expression at 14 and 90 days could distinguish responders from non-responders (AUC (95% CI) 0.849 (0.733 to 0.928) and 0.867 (0.755 to 0.941), respectively). This study reported for the first time that measurement of the circulating miR-146a expression at 14 days can predict the early response to imatinib treatment in patients with CML.
DOI:
10.1136/jim-2020-001563